(Q81049997)

English

Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells

scientific article published on 19 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Leishmania infantum

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Javier Carrión

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Cristina Folgueira

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Carlos Alonso

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

19 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

2537-2544

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Advances in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Leishmaniasis as an emerging infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Recent advances in vaccines for leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Molecular determinants and regulation of Leishmania virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Immunopathogenesis of infection with the visceralizing Leishmania species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Clinical spectrum of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

The immunology of Leishmania infection and the implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Immunohistological features of visceral leishmaniasis in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

DNA vaccines: immunology, application, and optimization*

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Dendritic cells as a tool to combat infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Dendritic cells: understanding immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Adoptive transfer of dendritic cells modulates immunogenesis and tolerogenesis in a neonatal model of murine cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

T helper (h)1/Th2 and Leishmania: paradox rather than paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Regulation of protective immunity against Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Functional genomics and immunological approaches toward a comprehensive view of protozoan parasite virulence factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Invasion, control and persistence of Leishmania parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Interleukin-10 and the pathogenesis of human visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Dendritic cells, new tools for vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Mechanisms of dendritic cell-based vaccination against infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

A Toll-like receptor recognizes bacterial DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Modulating vaccine responses with dendritic cells and Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

IL-12 Acts Directly on DC to Promote Nuclear Localization of NF-κB and Primes DC for IL-12 Production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

The biology of IL-12: coordinating innate and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.003

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.03.003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400342%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81049997&oldid=1985020109"